Holen Sie sich die Stockscreener-App
25.96
0.80%
-0.21
Vorhandelsmarkt:
26.01
0.05
+0.19%
Schlusskurs vom Vortag:
$26.17
Offen:
$26
24-Stunden-Volumen:
1.90M
Relative Volume:
0.90
Marktkapitalisierung:
$4.85B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-451.71M
KGV:
-8.0469
EPS:
-3.2261
Netto-Cashflow:
$-462.19M
1W Leistung:
+0.31%
1M Leistung:
+9.81%
6M Leistung:
+67.05%
1J Leistung:
+112.09%
1-Tages-Spanne:
$25.88
$26.48
1-Wochen-Bereich:
$25.25
$27.30
52-Wochen-Spanne:
$11.64
$27.30
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
25.96 | 4.89B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
DYN Company (Nasdaq: DYN) holder plans 4,986-share sale worth $131,034 - Stock Titan
DYN (DYN) insider notice details planned share sale and prior trades - Stock Titan
DYN (DYN) shareholder Doug Kerr plans sale of 2,443 common shares - Stock Titan
Dyne Therapeutics (DYN): Atlas Venture funds report 3.6% beneficial stake in 13G/A - Stock Titan
Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson - Stock Titan
Dyne Therapeutics stock hits 52-week high at 27.19 USD - Investing.com
Dyne Therapeutics stock hits 52-week high at 27.19 USD By Investing.com - Investing.com Canada
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
FMR LLC Expands Dyne Therapeutics Stake: A Strategic Bet on Neur - GuruFocus
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week HighHere's What Happened - MarketBeat
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial - simplywall.st
Discipline and Rules-Based Execution in DYN Response - Stock Traders Daily
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus - Sahm
Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Inc (DYN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingView
FMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing - Stock Titan
Dyne Therapeutics stock hits 52-week high at 26.8 USD By Investing.com - Investing.com UK
Dyne Therapeutics stock hits 52-week high at 26.8 USD - Investing.com
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 56% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Weekly Recap: BLA accepted for Z‑Rostudirsen and RBC raises PT to $35 - TradingView
Dyne Therapeutics, Inc. $DYN Shares Purchased by Renaissance Technologies LLC - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Purchased by Perceptive Advisors LLC - MarketBeat
DYNE THERAPEUTICS, INC : RBC RAISES TARGET PRICE TO $35 FROM $30 - webull.com
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $44 to $47 - Moomoo
Dyne Therapeutics, Inc. $DYN Shares Sold by Vivo Capital LLC - MarketBeat
RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Dyne Therapeutics (DYN) - The Globe and Mail
DYN SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Dyne Therapeutics reports Q2 net loss $178.6M, cash $898.5M; BLA for z-rostudirsen accepted with PDUFA Jan 21, 2027 - TradingView
Dyne Therapeutics Net Loss Widens to $178.6 Million in Q2 2026 - quiverquant.com
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy - Investing News Network
Dyne Therapeutics receives FDA clearance for FSHD trial - Investing.com
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application ... - Caledonian Record
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) - marketscreener.com
Dyne Therapeutics Announces U.S. FDA Clearance of - GlobeNewswire
Dyne Therapeutics Inc (DYN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (DYN holder) discloses 11.49M Dyne Therapeutics shares, a 7% stake - Stock Titan
Dyne Therapeutics stock hits 52-week high at 25.06 USD By Investing.com - Investing.com UK
ForDyne B.V. (DYN) files Rule 144 to potentially sell 261,460 common shares - Stock Titan
Dyne Therapeutics stock hits 52-week high at 25.06 USD - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey
Dyne Therapeutics Inc (DYN) Cash Flow - TradingKey
Dyne Therapeutics Inc (DYN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):